The Movement Disorders market is witnessing significant growth, driven by an increasing prevalence of disorders such as Parkinson's disease and essential tremor. Rising awareness, coupled with advancements in diagnostic technologies, contributes to early detection and intervention. Pharmaceutical companies are actively engaged in developing innovative therapies to address motor symptoms and improve the quality of life for affected individuals. Deep brain stimulation and other neuromodulation techniques are gaining prominence as effective treatment options. Additionally, collaborative research efforts and strategic partnerships are shaping the landscape of therapeutic interventions. Geographically, North America holds a substantial market share, attributed to a higher prevalence of movement disorders and well-established healthcare infrastructure. However, the Asia-Pacific region is emerging as a key market, driven by a growing aging population and increasing healthcare investments. Overall, the Movement Disorders market reflects dynamic advancements in diagnosis and treatment modalities.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
